Nasdaq Warns NuRAN Over Sub-$1 Bid, 180 Days to Regain Compliance
NUR is trading near its 52-week low of $0.364 (15% above the low).
Summary
NuRAN received a Nasdaq notification letter dated November 10 saying its bid price sat below US$1.00 for 30 straight business days, from September 29 to November 9. The shares keep trading on the Nasdaq Capital Market under NUR for now — this is a deficiency notice, not a delisting notice. The company has until May 10, 2027 to close at or above US$1.00 for at least ten consecutive business days, with a possible second 180-day window if it meets the US$1 million market value of publicly held shares test and other initial listing standards. Management says it will consider all options, including a reverse split, which Nasdaq requires be completed at least ten business days before the May 10, 2027 deadline. The clock is long but the setup is ugly: a micro-cap already running a US$50 million at-the-market program and a US$70.6 million shelf, now facing the dilution-or-reverse-split choice that typically precedes a Nasdaq cure.
At the time of this announcement, NUR was trading at $0.42 on NASDAQ in the Technology sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.36 to $147.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.